Company Filing History:
7 out of 1,360 
1 out of 1,154 Years Active: 2012-2019
Title: Seungjoo Haam: Innovator in Bioenvironment-Sensitive Nanoparticles
Introduction
Seungjoo Haam is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of nanotechnology, particularly in the development of bioenvironment-sensitive nanoparticles. With a total of 7 patents to his name, his work focuses on innovative solutions for drug delivery and cancer treatment.
Latest Patents
One of his latest patents is titled "Bioenvironment-sensitive nanoparticle comprising polymer having complementary charges." This invention discloses a bioenvironment-sensitive nanoparticle that includes a polymer with complementary charges. The nanoparticle is designed to stably and effectively deliver target materials, such as drugs, even in small quantities. It is particularly useful for selectively diagnosing or treating cancer cells due to its specificity to the environments of these cells.
Another notable patent is "Polyaniline coordinated with transition metal and preparation method thereof." This patent provides methods for preparing polyaniline coordinated with a transition metal, along with a core-shell nanoparticle that includes this polyaniline as a core. The preparation process is simplified, and the resulting polyaniline exhibits improved dispersibility in solvents, along with easily regulated band gap levels.
Career Highlights
Seungjoo Haam has worked at prestigious institutions such as Yonsei University and Korea University Research and Business Foundation. His research has significantly advanced the understanding and application of nanoparticles in medical fields.
Collaborations
He has collaborated with notable colleagues, including Hyun-Ouk Kim and Yong-min Huh, contributing to various research projects and innovations.
Conclusion
Seungjoo Haam's work in the field of bioenvironment-sensitive nanoparticles showcases his dedication to advancing medical technology. His innovative patents reflect his commitment to improving drug delivery systems and cancer treatment methodologies.